76 drug prices are not in place, or will be removed from the Internet

[industry trends of pharmaceutical network] recently, Guangxi issued the notice on urging the price reduction of imported drugs and anti-cancer drugs (hereinafter referred to as the notice) During the period, it was emphasized that manufacturers should apply for price reduction in accordance with the requirements of the notice on receiving the application materials for adjusting the price of the shortlisted imported drugs and anti-cancer drugs by centralized purchase of drugs from medical and health institutions in Guangxi Zhuang Autonomous Region in 2015, which was put online on July 24, 2018 According to the list of drugs with no price reduction after tax attached to the notice, 76 drugs, including bxiao'an, goserellin acetate, and dicithabine, were not in place, while some drugs, such as cyclophosphamide and methotrexate, were not in place According to the notice, if the price reduction information of drug manufacturers has not been submitted by the deadline, the varieties that have not applied for price reduction will be submitted to Guangxi Medical Insurance Bureau at that time to decide to stop the online trading qualification In fact, Guangxi issued the "notice" to urge the import of drugs and anti-cancer drugs to declare the price reduction, which is to urge the price reduction of drugs, and is not a special case Since this year, a number of provinces and cities of drugs have been removed due to inadequate price reduction In January, Hainan public resources trading service center issued the notice of Hainan Province on publicizing the price reduction results of anticancer drugs in 2019 According to the National Health Insurance Bureau's "103 kinds of anti-cancer drugs (13 kinds) without price cut for tax reducing drugs", Hainan Province involves 8 varieties in total According to the requirements of Hainan Medical Insurance Bureau, the network was removed for failing to submit the application for price reduction or audit certificate, including vincristine sulfate for injection of Guangdong Lingnan Pharmaceutical Co., Ltd., mercaptopurine tablets of Zhejiang Zhebei Pharmaceutical Co., Ltd., etc   On May 14, Shaanxi issued the notice on the handling results of complaints about the dynamic adjustment of public notice period for the purchase of drugs through the conformity evaluation varieties of generic drugs (hereinafter referred to as the notice), which not only put forward the requirements of low price for the varieties passing the conformity evaluation, but also made it clear that the price of "4 + 7" related varieties declared in the evaluated varieties is higher than the price of "4 + 7" online products will not be temporarily Hang up the net At the same time, for the pilot city of Xi'an, because the price does not meet the relevant requirements, 8 drugs will not be connected to the Internet in all public medical and health institutions in Xi'an Subsequently, Shandong provincial drug centralized purchase network also issued a notice to remove 51 drugs from the network and withdraw from the hospital market in Shandong Province Among the 51 products removed from the network, there are many large varieties of well-known enterprises, including paclitaxel injection, pemetrexed disodium for injection, methotrexate for injection and other products Earlier, the notice on the implementation of tax reduction and price reduction results of domestic anticancer drugs issued by Liaoning Province showed that two drugs which stated that they were not affected by tax reduction and did not apply for price reduction and did not provide relevant certification materials of accounting firm, 57 drugs whose reduction did not meet the requirements and 66 drugs which did not make any response were suspended from online procurement in Liaoning Province In recent years, the government has been pushing for the price reduction of generic drugs As long as drug companies want to keep their own drugs online, they have to apply for the price reduction It can be predicted that with the promotion of a series of policies such as two vote system, 4 + 7 national centralized procurement, medical insurance control fees, drug price reduction will become a normalization In order to achieve win-win results and achieve coordinated development between profit growth and people's livelihood, relevant pharmaceutical enterprises should actively "think about change" Some insiders said that under the continuous pressure of pharmaceutical enterprises, cost control will be the key to the development of enterprises On the one hand, pharmaceutical companies should take the initiative to cater to the national tariff reduction policy, on the other hand, they need to accelerate innovation and upgrading, and actively embrace the Internet, control costs on the basis of quality, so as to have a better future.